Form 4: Avalo Therapeutics CFO Sells Shares
Insider Transaction (Form 4)
Christopher Ryan Sullivan, Chief Financial Officer of Avalo Therapeutics, Inc., sold 72,725 shares of common stock on August 17, 2026.
Summary
- Option exercise/conversion: acquired 37,945 Common Stock at $9.88 ($374,897) on August 17, 2026; holds 78,718 after (Direct).
- Option exercise/conversion: acquired 2,876 Common Stock at $9.88 ($28,415) on August 17, 2026; holds 81,594 after (Direct).
- Open-market sale: disposed of 37,945 Common Stock at $19.85 ($753,333) on August 17, 2026; holds 43,649 after (Direct).
- Open-market sale: disposed of 3,749 Common Stock at $19.94 ($74,762) on August 17, 2026; holds 39,900 after (Direct).
- Option exercise/conversion: acquired 31,031 Common Stock at $9.88 ($306,586) on August 18, 2026; holds 70,931 after (Direct).
- Open-market sale: disposed of 31,031 Common Stock at $20.05 ($622,324) on August 18, 2026; holds 39,900 after (Direct).
- Option exercise/conversion: disposed of 37,945 Stock Option (Right to Buy) on August 17, 2026; holds 130,149 after (Direct).
- Option exercise/conversion: disposed of 2,876 Stock Option (Right to Buy) on August 17, 2026; holds 127,273 after (Direct).
- Option exercise/conversion: disposed of 31,031 Stock Option (Right to Buy) on August 18, 2026; holds 96,242 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $1,450,419 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Christopher Ryan Sullivan — Officer (Chief Financial Officer)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-17 | Option exercise/conversion | Common Stock | 37,945 | $10 | $374.9K | 78,718 |
| 2026-08-17 | Option exercise/conversion | Common Stock | 2,876 | $10 | $28.4K | 81,594 |
| 2026-08-17 | Open-market sale | Common Stock | 37,945 | $20 | $753.3K | 43,649 |
| 2026-08-17 | Open-market sale | Common Stock | 3,749 | $20 | $74.8K | 39,900 |
| 2026-08-18 | Option exercise/conversion | Common Stock | 31,031 | $10 | $306.6K | 70,931 |
| 2026-08-18 | Open-market sale | Common Stock | 31,031 | $20 | $622.3K | 39,900 |
| 2026-08-17 | Option exercise/conversion | Stock Option (Right to Buy) | 37,945 | — | — | 130,149 |
| 2026-08-17 | Option exercise/conversion | Stock Option (Right to Buy) | 2,876 | — | — | 127,273 |
| 2026-08-18 | Option exercise/conversion | Stock Option (Right to Buy) | 31,031 | — | — | 96,242 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-17 | Option exercise/conversion (37,945 shares) |
| 2026-08-17 | Option exercise/conversion (2,876 shares) |
| 2026-08-17 | Open-market sale (37,945 shares) |
| 2026-08-17 | Open-market sale (3,749 shares) |
| 2026-08-18 | Option exercise/conversion (31,031 shares) |
| 2026-08-18 | Open-market sale (31,031 shares) |
| 2026-08-17 | Option exercise/conversion (37,945 shares) |
| 2026-08-17 | Option exercise/conversion (2,876 shares) |
| 2026-08-18 | Option exercise/conversion (31,031 shares) |
Keywords
insider transaction, Form 4, AVTX, Avalo Therapeutics, Inc., bearish, Christopher Ryan Sullivan
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.